Grifols, S.A. (GRFS) News
Filter GRFS News Items
GRFS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GRFS News Highlights
- For GRFS, its 30 day story count is now at 3.
- Over the past 2 days, the trend for GRFS's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about GRFS are STVN.
Latest GRFS News From Around the Web
Below are the latest news stories about GRIFOLS SA that investors may wish to consider to help them evaluate GRFS as an investment opportunity.
GRFS or STVN: Which Is the Better Value Stock Right Now?GRFS vs. STVN: Which Stock Is the Better Value Option? |
Grifols (GRFS) Upgraded to Strong Buy: What Does It Mean for the Stock?Grifols (GRFS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). |
Should Value Investors Buy Grifols (GRFS) Stock?Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
Grifols Accelerates Healthcare Innovation with Google Cloud’s AI and AnalyticsGrifols will apply artificial intelligence technologies, including large language models, to speed up the development of new biopharma therapeuticsAgreement is latest Grifols initiative to reinforce the robustness of its therapeutic pipeline and strengthen its innovation culture BARCELONA, Spain, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines that has been enhancing people’s health and |
Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for PatientsClinical trial met primary endpoint demonstrating comparable total immunoglobulin (Ig) levels when administering XEMBIFY® (Grifols’ subcutaneous Ig) every two weeks, compared with weekly, in patients with primary immunodeficienciesStudy designed to support extending U.S. Food and Drug Administration labeling of XEMBIFY® to include biweekly dosing, providing added flexibility and convenience for patientsGrifols is accelerating adoption of XEMBIFY® as part of its broader immunoglobulin business st |
Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated CirrhosisPRECIOSA clinical trial is designed to evaluate efficacy and safety of Grifols Albutein® plus standard medical treatment to increase survival time in patients with decompensated cirrhosis awaiting transplantAlbumin’s antioxidant and anti-inflammatory properties have the potential to mitigate the complications associated with decompensated cirrhosisGrifols continues innovating across its plasma-protein franchise and is committed to applying its ever-growing expertise in a range of therapeutic are |
Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin®-C in Patients with Emphysema Due to Alpha-1-Antitrypsin DeficiencyTarget of 339 patients enrolled has been met in the SPARTA clinical trial, designed to evaluate efficacy and safety of two separate weekly doses of Grifols’ Prolastin®-C (Alpha1-Proteinase Inhibitor [Human]) to slow emphysema progression in patients with alpha-1-antitrypsin (AAT) deficiency (known as alpha-1)Alpha-1 is the most common genetic risk factor for chronic obstructive pulmonary disease (COPD), a group of respiratory diseases that includes emphysema. COPD is the third leading cause of d |
Grifols shares soar on possible sale of $1.5 billion stake in Shanghai RAASShares in Spanish pharmaceutical Grifols soared on Wednesday morning after it disclosed a plan to reduce its stake in Shanghai RAAS in a deal that would bring in $1.5 billion. Shares in Grifols, which produces drugs made out of blood plasma, were up 8.0% in morning trade after the company announced it was planning to change the shareholding structure in the Chinese company, of which it owns 26.20%. Grifols would receive $1.5 billion if the deal goes ahead, the Spanish company said, without disclosing a buyer. |
Grifols Launches AlphaID™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic COPDNow available in the U.S., this free, innovative genetic health risk service lets consumers screen for their risk of alpha1-antitrypsin deficiency (alpha-1) through a small saliva sample they can collect right at home without needing to visit a healthcare professionalAlpha-1 is the most common genetic risk factor for chronic obstructive pulmonary disease (COPD), a group of respiratory diseases affecting around 16 million Americans and the fourth-leading cause of death in the U.S.1As the leader i |
Why Shares of Grifols Were Up TuesdayShares of Grifols (NASDAQ: GRFS) were up 11.1% on Tuesday afternoon, after being up as much as 13.1% earlier in the day. The pharmaceutical company, which makes plasma-derived medicines, released first-quarter earnings on Tuesday morning. The company's products range from diagnostics to detect infectious agents in blood or plasma donations, to the production of antigens used in immunoassay regents, to albumin, used to restore circulatory volume and protein loss in certain conditions. |